December 8, 2014
The Pharmaceuticals and Medical Devices Agency (PMDA) announced on December 5 that five sodium-glucose co-transporter-2 (SGLT-2) inhibitors including ipragliflozin L-proline (product name: Suglat from Astellas Pharma) are being evaluated for the potential risk of dehydration. Certain safety measures including the...read more